$556.75
9.101.66%
近くで: Sep 2, 5:00 PM EST
$557.00
0.250.04%
時間外: 7:27 PM EST
Benzinga
Benzinga
Benzinga
木曜日, 9 03
Vertex Pharmaceuticals Inc
VRTXNASDAQ
M&A: Crinetics Pharmaceuticals (CRNX) was acquired by Vertex Pharmaceuticals (VRTX) on Tuesday, September 1, 2026 for $10B paid in cash
Vertex Pharmaceuticals Earnings & Forecasts
Vertex Pharmaceuticals (VRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vertex Pharmaceuticals Guidance
Vertex Pharmaceuticals (VRTX) は、8 3, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$13.1B - $13.2Bの範囲と予想しています。
以前のガイダンスと比較して、Vertex Pharmaceuticalsは売上高予測を以前の範囲である維持から$12.95B - $13.1Bに引き上げました。
Vertex Pharmaceuticalsは、16から10 27, 2022の間に8 3, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $4.63 | $4.18 | $4.85 | $4.35 |
| Actual | $4.73 | $4.47 | $5.03 | $4.80 |
| Surprise | +2.16% | +6.94% | +3.71% | +10.3% |
| Revenue | ||||
| Estimate | $3.21B | $2.99B | $3.17B | $3.05B |
| Actual | $3.33B | $2.99B | $3.19B | $3.08B |
| Surprise | +3.74% | -0.24% | +0.54% | +0.80% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $4.81 | $4.80 | $4.64 | $4.88 |
| Revenue | ||||
| Consensus | $3.40B | $3.50B | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved